Category: Edwards Lifesciences
A study of replacement heart valves treated with calcification-reducing coatings shows that the coatings prolong valve durability.
Edwards Lifesciences halts enrollment in a clinical trial of its Fortis mitral valve implant after some patients developed blood clots in the devices.
Edwards Lifesciences CEO Michael Mussallem says the company now expects the FDA to approve its next-generation Sapien 3 replacement heart valve this year.
Screening coronary artery disease patients using computed-tomography angiography is no better than functional testing in improving outcomes, according to a large clinical study by the National Heart, Lung & Blood Institute, plus more from the annual meeting of the American College of Cardiology.
A large clinical trial comparing computed-tomography angiography with functional testing found no benefit to clinical outcomes with CTA, which also exposes patients to large doses of radiation.
A Danish study presented at the American College of Cardiology's annual conference shows that transcatheter aortic valve implants are safe in low-risk patients.
(Reuters) — Transcatheter aortic valve implantation is safe for low-risk patients, according to a study presented at the American College of Cardiology meeting in San Diego.
Replacement heart valves made by Edwards Lifesciences and Medtronic once again dominate the American College of Cardiology's annual meeting, with long-term results for Edwards' Sapien and Medtronic's CoreValve complemented by even better data from their next-generation transcatheter aortic valve implants.
Transcatheter aortic valve implants once again took the spotlight at the annual meeting of the American College of Cardiology, with a spate of studies both confirming the long-term benefits of the replacement heart valves and showing that newer TAVI versions are even better.
The lobbying spend in Washington hit a 16-year high of nearly $33 million in 2014, as the industry continued its fight to repeal Obamacare's medical device tax.
The medical device industry's lobbying spend hit its highest point since 1998 last year, nearing $33 million, as the industry stepped up its campaign to repeal the medical device tax enacted as part of Obamacare.